Focus Taiwan App

Product warning issued for weight loss drug Belvic: FDA

02/14/2020 11:41 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Feb. 14 (CNA) Taiwan's Food and Drug Administration (FDA) on Friday issued a product warning for the weight loss drug Belviq, after American medical authorities reported on Thursday that clinical trials on the drug's active ingredient, lorcaserin, showed an increased risk of several types of cancer.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.